Molecular Partners AG (NASDAQ:MOLN – Get Free Report) shares traded down 5.4% on Wednesday . The company traded as low as $6.46 and last traded at $6.62. 6,663 shares changed hands during trading, a decline of 70% from the average session volume of 22,482 shares. The stock had previously closed at $7.00.
Molecular Partners Stock Performance
The company has a 50-day moving average of $5.00 and a 200-day moving average of $4.55. The stock has a market capitalization of $242.83 million, a price-to-earnings ratio of -3.28 and a beta of 1.04.
Molecular Partners (NASDAQ:MOLN – Get Free Report) last posted its quarterly earnings data on Thursday, May 16th. The company reported ($0.39) EPS for the quarter. Molecular Partners had a negative net margin of 864.64% and a negative return on equity of 31.42%. The company had revenue of $3.13 million for the quarter. As a group, analysts expect that Molecular Partners AG will post -2.22 earnings per share for the current year.
Molecular Partners Company Profile
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
See Also
- Five stocks we like better than Molecular Partners
- Canadian Penny Stocks: Can They Make You Rich?
- AbbVie Stock: A Perfect Dip for Investors to Buy
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- What Makes a Stock a Good Dividend Stock?
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.